Market Place
Sourcing Support
LEO Pharma’s Anzupgo® Cream Approved in Switzerland
14 Nov 2024 //
BUSINESSWIRE
LEO Pharma Reports Double-Digit Growth in Dermatology Sales
31 Oct 2024 //
BUSINESSWIRE
LEO Pharma Presents ECZTEND Trial Results for Adbry® in AD
25 Oct 2024 //
BUSINESSWIRE
LEO Pharma Presents Adbry® and Delgocitinib Data at Conference
23 Oct 2024 //
BUSINESSWIRE
LEO Pharma Launches Campaign For Chronic Hand Eczema
22 Oct 2024 //
BUSINESSWIRE
Germany Becomes First Country to Launch LEO Pharma’s Anzupgo Cream
15 Oct 2024 //
BUSINESSWIRE
LEO Pharma Commits to Net-Zero Greenhouse Gas Emissions by 2050
11 Oct 2024 //
BUSINESSWIRE
Leo Pharma to chop or relocate 250 roles under ongoing revamp
09 Oct 2024 //
FIERCE PHARMA
LEO Pharma Submits NDA For Enstilar In China For Plaque Psoriasis
27 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents Tralokinumab Data At EADV 2024 For AD
27 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents Temtokibart Results At EADV Meeting
26 Sep 2024 //
BUSINESSWIRE
LEO Presents Extensive Data of 5 Late Breaking Abstracts At EADV
25 Sep 2024 //
BUSINESSWIRE
LEO Pharma Presents Anzupgo® Data At EADV 2024
25 Sep 2024 //
BUSINESSWIRE
FDA Accepts LEO Pharma`s Delgocitinib Cream NDA For CHE
23 Sep 2024 //
BUSINESSWIRE
EC Approves LEO Pharma`s Anzupgo For Chronic Hand Eczema
23 Sep 2024 //
BUSINESSWIRE
Leo Pharma`s Anzupgo (delgocitinib) Receives Approval in Europe
19 Sep 2024 //
EMA
Adbry Autoinjector Available For Moderate-To-Severe Atopic Dermatitis Treatment
17 Sep 2024 //
BUSINESSWIRE
LEO Pharma Shows Largest Data on Chronic Hand Eczema at ESCD 2024
05 Sep 2024 //
BUSINESSWIRE
LEO Pharma Reports 11% Revenue Growth In H1, Upgrades Financial Outlook
26 Aug 2024 //
BUSINESSWIRE
LEO Pharma Gets CHMP Nod For Anzupgo In Chronic Hand Eczema
25 Jul 2024 //
BUSINESSWIRE
LEO Pharma Publishes Phase 3 Data On Chronic Hand Eczema
18 Jul 2024 //
BUSINESSWIRE
FDA Approves Adbry Autoinjector fo Adults with Moderate-to-Severe (AD)
13 Jun 2024 //
BUSINESSWIRE
Leo’s single-dose autoinjector secures FDA approval for atopic dermatitis
13 Jun 2024 //
PHARMACEUTICAL TECHNOLOGY
Leo Pharma As Biologic Tralokinumab Receives Supp Approval in US
12 Jun 2024 //
FDA
LEO Pharma China Psoriasis Phase 3 Data For Enstilar
07 May 2024 //
BUSINESSWIRE
LEO Pharma Delivers 13% Growth On Dermatology Performance
03 May 2024 //
BUSINESSWIRE
In year 2 under new CEO, troubled Leo Pharma makes progress
12 Mar 2024 //
FIERCE PHARMA
Timber Pharmaceuticals Presents Late-Breaking Preliminary Results of TMB-001
10 Mar 2024 //
BUSINESSWIRE
LEO Unveils Late-Breaking Data for Landmark DELTA 3 Open-Label Extension Trial
09 Mar 2024 //
BUSINESSWIRE
LEO Pharma Presents New Long-Term Adbry® (tralokinumab-ldrm) Data
08 Mar 2024 //
BUSINESSWIRE
LEO Pharma to Maintain Leadership Role at AAD in 2024
06 Mar 2024 //
BUSINESSWIRE
LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA
29 Feb 2024 //
BUSINESSWIRE
Leo Pharma builds its case for JAK inhibitor cream delgocitinib
24 Jan 2024 //
FIERCE PHARMA
LEO Pharma Finalizes Acquisition of Key Assets From Timber Pharmaceuticals
23 Jan 2024 //
BUSINESSWIRE
LEO Pharma Presents Data at 2024 Winter Clinical and Maui Derm Conferences
12 Jan 2024 //
BUSINESSWIRE
LEO Pharma Inc. Announces U.S. FDA approval of Adbry
15 Dec 2023 //
BUSINESSWIRE
Leo Pharma`s Biologic Adbry (tralokinumab) Receives Approval in the U.S.
14 Dec 2023 //
FDA
LEO Pharma Announces Positive Outcome of DELTA 3 Trial of Delgocitinib
30 Oct 2023 //
BUSINESSWIRE
LEO Pharma Presents Adbry Data at 2023 Fall Clinical Dermatology Conference
20 Oct 2023 //
BUSINESSWIRE
LEO Pharma Presents New Long-Term Data on Use of Adtralza
13 Oct 2023 //
BUSINESSWIRE
Leo unveils detailed results on JAK cream win in hand eczema
13 Oct 2023 //
FIERCE PHARMA
LEO Connects Affiliates with Veeva Vault Safety to Transform Safety Operations
03 Oct 2023 //
PR NEWSWIRE
LEO Pharma delivers solid first half-year results
12 Sep 2023 //
BUSINESSWIRE
Leo Pharma spending $14M upfront to acquire Timber
21 Aug 2023 //
ENDPTS
EMA Accepts LEO Pharma’s MAA for Delgocitinib Cream in CHE
18 Aug 2023 //
BUSINESSWIRE
LEO Pharma Receives Positive CHMP Opinion for New Adtralza
23 Jun 2023 //
BUSINESSWIRE
Leo Pharma`s Biologic Adbry (Tralokinumab) Receives Approval in the U.S.
02 Jun 2023 //
FDA
Leo censured for ‘extremely concerning` drug marketing breach
31 Mar 2023 //
FIERCE PHARMA
LEO Pharma Presents Positive Phase 2a Efficacy Results of LEO 138559
18 Mar 2023 //
BUSINESSWIRE
LEO Presents Adbry Data in Population from ECZTRA 6 and ECZTEND Trials
17 Mar 2023 //
BUSINESSWIRE
LEO Adds Internationally Recognized Dermatologist to Global Leadership Team
14 Mar 2023 //
BUSINESSWIRE
Further shuffling at Leo Pharma as dermatology drugmaker splits R&D
14 Mar 2023 //
ENDPTS
LEO Pharma and ICON Enter a Strategic Partnership to Propel Trial Execution
10 Mar 2023 //
BUSINESSWIRE
LEO Pharma, ICON Partner to Advance Clinical Trials in Dermatology
10 Mar 2023 //
CONTRACT PHARMA
Leo Pharma scores in phase 3 trial for JAK inhibitor cream
13 Feb 2023 //
FIERCE PHARMA
LEO Announces Positive PIII Results From DELTA 2 Trial With Delgocitinib
10 Feb 2023 //
BUSINESSWIRE
Japan Approves Manufacturing and Marketing of Adtralza in Japan
24 Dec 2022 //
BUSINESSWIRE
Japan Ministry of Health Approves Manufacturing and Marketing of Adtralza
23 Dec 2022 //
BUSINESSWIRE
Leo`s JAK inhibitor cream posts positive results for hand eczema
06 Dec 2022 //
FIERCEPHARMA
